A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Inclusion criteria: * Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma as per IW-CLL 2008 criteria and require therapy based on meeting at least one of the following criteria: * Evidence of progressive marrow failure with anemia (hemoglobin \<11.0 g/L) and/or thrombocytopenia (platelets \<100 x 10\^9/L) * Massive (≥6 cm below the left costal margin), progressive, or symptomatic splenomegaly * Massive nodes (at least 10 cm longest diameter), progressive, or symptomatic lymphadenopathy * Progressive lymphocytosis with an increase of more than 50% over a 2-month period or LDT of \<6 months. * Autoimmune anemia and/or thrombocytopenia that is poorly responsive to corticosteroids * Constitutional symptoms, defined as 1 or more of the following: * unintentional weight loss \>10% within 6 months prior to screening * significant fatigue (inability to work or perform usual activities) fevers \>100.5° F or 38.0° C for 2 or more weeks prior to screening without evidence of infection * night sweats for more than 1 month prior to screening without evidence of infection * Relapsed after or refractory to at least one prior Chronic Lymphocytic Leukemia-directed therapy * Age greater than or equal to 18 years * ECOG Performance Status \<2 * Heme criteria at screening, unless significant bone marrow involvement of Chronic Lymphocytic Leukemia confirmed on biopsy: * Absolute Neutrophil Count (ANC) ≥500 cells/mm3 (0.5 x 10\^9/L). Growth factor allowed to achieve * Platelet count ≥25,000 cells/mm3 (25 x 10\^9/L) independent of transfusion within 7 days of screening * Adequate hepatic function defined as: AST and ALT ≤ 4.0 x upper limit of normal (ULN), bilirubin ≤2.0 x upper limit of normal (ULN) unless bilirubin rise is due to Gilbert's syndrome) * Adequate renal function defined by serum creatinine \<2.0 x upper limit of normal (ULN) unless due to biopsy proven Chronic Lymphocytic Leukemia kidney infiltration * Women of child-bearing potential and men must agree to use adequate contraception * Patients who have undergone prior allo transplant are eligible provided that their transplant day 0 is \> 6 months from their first dose of study drug Exclusion Criteria: * History of severe allergic or anaphylactic reactions to monoclonal antibody therapy * Prior treatment with either obinutuzumab or ibrutinib * History of other malignancies, except: * Malignancy treated with curative intent and with no known active disease present for ≥3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician. * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. * Adequately treated carcinoma in situ without evidence of disease. * Low-risk prostate cancer on active surveillance * Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc., or chronic administration of \>20 mg/day of prednisone) within 28 days of the first dose of study drug. * Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug. * Recent infection requiring systemic treatment that was completed ≤7 days before the first dose of study drug. * Known bleeding disorders or hemophilia. * History of stroke or intracranial hemorrhage within 6 months prior to enrollment. * Known history of HIV or active hepatitis C virus (HCV) or hepatitis B virus (HBV). * Any uncontrolled active systemic infection. * Major surgery within 4 weeks of first dose of study drug. * Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 CHF as defined by the NYHA Functional Classification; or a history of Myocardial Infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization. * Lactating or pregnant. * Patients receiving any other study agents * Patients with known Central Nervous System involvement * Baseline QT Interval Corrected by the Fridericia Correction Formula (QTcF) \>480 ms unless Left Bundle Branch Block * Patients who require warfarin or other vitamin K antagonists for anticoagulation * Concurrent administration of strong inhibitors or inducers of CYP3A